S. Armstrong

发表

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

J. Budman, U. Klein, Cécile Yu, 2011, Journal of cardiovascular pharmacology.

A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.

S. D. Turner, J. Shaw, S. Choi, 2009, Journal of medicinal chemistry.

In Vitro Isolated Tissue Functional Muscarinic Receptor Assays

R. Eglen, S. Hegde, N. Watson, 2010, Current protocols in pharmacology.

In Vivo Pharmacodynamic Assays for M2 and M3 Muscarinic Receptors

S. Hegde, T. Steinfeld, M. Pulido-Rios, 2010, Current protocols in pharmacology.

Pharmacological analysis of the interaction of antimuscarinic drugs at M2 and M3 muscarinic receptors in vivo using the pithed rat assay

B. Horger, S. Hegde, S. Jaw-Tsai, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.

J. Shaw, R. Vickery, D. Long, 2013, Bioorganic & medicinal chemistry letters.

Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.

J. Shaw, S. Choi, R. Vickery, 2012, Bioorganic & medicinal chemistry letters.

The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties

O. Daniels, K. Kersey, R. Vickery, 2011, Front. Pharmacol..

The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist

R. Vickery, Pamela R. Tsuruda, D. Long, 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.

S. D. Turner, J. Shaw, S. Choi, 2012, Bioorganic & medicinal chemistry letters.

Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition.

Frédérick A. Mallette, C. Yohn, C. Beauséjour, 2021, Cell metabolism.

Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.

M. Mammen, J. Jasper, S. Hegde, 2009, European journal of pharmacology.

The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity

R. Vickery, Pamela R. Tsuruda, Christina B. Campbell, 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

The 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivo

R. Vickery, T. Pulido-Rios, J. A. Smith, 2004, British journal of pharmacology.

Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

P. Colson, R. Vickery, Pamela R. Tsuruda, 2019, ACS medicinal chemistry letters.

Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat.

D. Beattie, S. Armstrong, J. L. McCullough, 2006, Journal of pharmacological and toxicological methods.

The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat.

D. Beattie, S. Hegde, S. Armstrong, 2006, Pharmacological research.

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

J. Taylor, J. Shaw, J. A. Smith, 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist

R. Vickery, D. Long, D. Beattie, 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.